UTTAR PRADESH JOURNAL OF ZOOLOGY

Our current work focuses on the CHRNA5 protein's susceptibility to lung cancer. This gene encodes nicotinic acetylcholine receptor subunits, which are ligand-gated ion channels that speed up signal transmission at synapses. A higher incidence of type 2 lung cancer (Non-Small Cell Lung Cancer (NSCLC)) has been linked to gene abnormalities. The primary purpose of this study is to investigate the efficacy of Cordia dichotoma-derived ZnO nanoparticles when combined with an existing anticancer drug against the mutant CHRNA5 of humans and Gorilla gorilla. Both humans and Gorillas are orthologous species as they share a similar sequence homology. The probable mutant areas were first identified using protein modelling tools and visualizers, and their three-dimensional structures studied. After modelling, we employed an automated docking service to link the modelled protein to our chosen molecule.  Discovery Studio Software, a powerful molecular visualization tool, was utilized to confirm the electrostatic interactions between the ligand and protein complex. Our chosen nano particles’ efficacy against the CHRNA5 protein was validated by binding interactions. Based on the docking scores and H-bond interactions, we conclude that the chosen molecule has the potential to be a promising Lung Cancer therapeutic agent. The drug was also tested against Gorilla gorilla to prove its efficiency against a homologous species. Our current study can be expanded into the areas of Clinical Oncology and Pharmacoinformatics.